These results led us to hypothesize that HS6ST2 expression, as determined by IHC, may be a useful biomarker for CRC diagnosis and prognosis in CRC patients receiving adjuvant chemotherapy. This evidence concerns the gene HS6ST2 and colorectal carcinoma.